Pharmaceutical industry analyst Andrew Baum is leaving banking to join Pfizer Inc. He will step into the position of chief strategy and innovation officer as an exec VP reporting to CEO Albert Bourla. Baum will have an important role in advancing Pfizer’s long-term corporate strategy, responsible for portfolio analysis and prioritization, business development, partnering and the commercial evaluation of the company’s pipeline.
Pfizer Recruits Industry Analyst Baum To Advance Corporate Strategy
Longtime pharmaceutical industry analyst Andrew Baum will join Pfizer’s executive leadership team.
More from Leadership
• By
The UK giant is forecasting peak sales of $5bn plus
• By
The small interference RNA therapeutic can be used by patients regardless of inhibitor status.
Recent moves in the industry include C-suite changes at Cronos and Accuryn Medical, plus Dyne Therapeutics Acquires Chief Financial Officer From Editas Medicine.
• By
The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.
More from Scrip
• By
The small interference RNA therapeutic can be used by patients regardless of inhibitor status.
• By
Senior executives from AstraZeneca, BMS, Novo Nordisk, Takeda and Regeneron outline how big pharma's global capability centers (GCCs) in India are evolving beyond cost efficiency, focusing on innovation, “agile experimentation” and new technology including GenAI, virtual & augmented reality, with some positioned as COEs. Will Indian multinationals use the GCC approach?
• By
In this week's episode: Merck & Co. licenses Hengrui’s lipid lowerer; Novo gets United’s triple G obesity drug; J&J plans major US manufacturing investments; approval for GSK’s novel antibiotic; and a call for more aggressive Korean M&A activity.